FY2023 Earnings Estimate for Global Blood Therapeutics Inc Issued By Wedbush (NASDAQ:GBT)
Global Blood Therapeutics Inc (NASDAQ:GBT) – Research analysts at Wedbush cut their FY2023 earnings per share (EPS) estimates for shares of Global Blood Therapeutics in a research report issued on Monday, August 12th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of $5.28 per share for the year, down from their previous forecast of $5.29. Wedbush currently has a “Outperform” rating and a $103.00 target price on the stock.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.05). During the same quarter in the previous year, the company earned ($0.78) earnings per share.
Shares of Global Blood Therapeutics stock opened at $46.68 on Wednesday. Global Blood Therapeutics has a one year low of $30.15 and a one year high of $64.94. The stock’s fifty day moving average is $53.99 and its 200 day moving average is $54.82. The stock has a market cap of $2.86 billion, a P/E ratio of -13.69 and a beta of 1.51. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.79 and a current ratio of 16.79.
Large investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new position in shares of Global Blood Therapeutics during the second quarter valued at about $27,000. Truvestments Capital LLC purchased a new position in shares of Global Blood Therapeutics during the first quarter valued at about $33,000. Captrust Financial Advisors purchased a new position in shares of Global Blood Therapeutics during the second quarter valued at about $42,000. NumerixS Investment Technologies Inc purchased a new position in shares of Global Blood Therapeutics during the second quarter valued at about $63,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Global Blood Therapeutics by 17.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock valued at $172,000 after purchasing an additional 482 shares in the last quarter.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Featured Story: Futures Contract
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.